Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €21.53 EUR
Change Today -0.05 / -0.23%
Volume 28.3K
As of 1:23 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc (GS7) Snapshot

Open
€21.54
Previous Close
€21.58
Day High
€22.04
Day Low
€21.31
52 Week High
04/14/15 - €22.95
52 Week Low
12/15/14 - €16.10
Market Cap
104.8B
Average Volume 10 Days
64.0K
EPS TTM
--
Shares Outstanding
4.9B
EX-Date
02/19/15
P/E TM
--
Dividend
€81.63
Dividend Yield
5.30%
Current Stock Chart for GLAXOSMITHKLINE PLC (GS7)

glaxosmithkline plc (GS7) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

97,921 Employees
Last Reported Date: 02/26/15
Founded in 1935

glaxosmithkline plc (GS7) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 2.0M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 1.2M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $2.3M
Compensation as of Fiscal Year 2014.

glaxosmithkline plc (GS7) Key Developments

Chicago Law Firm Files Nationwide Class Action Lawsuit Against GlaxoSmithKline

Chicago law firm announced it is considering filing the first nationwide class action lawsuit against GlaxoSmithKline (GSK), the makers of Zofran, a powerful anti-nausea drug alleged to increase the risk of birth defects when used by pregnant women, particularly during the first trimester. Moll Law Group reports that, based on a federal investigation, the U.S. Department of Justice (DOJ) announced that GSK agreed to plead guilty and pay $3 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of certain prescription drugs, including Zofran. The law firm notes, however, that this ruling does not specifically address the severe fetal defects that Zofran allegedly may cause.

GlaxoSmithKline to Close its Consumer Health Care Operations in Moon

GlaxoSmithKline will close its consumer health care operations in Moon by the end of the year 2015, eliminating 274 jobs and ending a nearly four-decade presence in the Pittsburgh region. The division, whose products include Aquafresh toothpaste and Tums antacids, has been in its current location overlooking the Parkway West near the Mall at Robinson since 2002.

The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute Collaborate with Glaxosmithkline on New ALS Clinical Trial

The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute announced they are collaborating with GlaxoSmithKline (GSK) on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. In parallel testing, brain cells will be made from each patient's stem cells to see if they can predict which patients might respond to the medicine. The trial will evaluate the potential of the drug, Retigabine, which has a unique mechanism of action and can calm the excitability of nerve cells that are thought to cause seizures. These 'hyperexcitable neurons' are also thought to play a role in ALS. Alongside testing of the medicine, scientists will for the first time create stem cells from these patients to see if they can be used to determine in advance which patients could benefit from the medicine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GS7:GR €21.53 EUR -0.05

GS7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $65.25 USD -0.82
Actavis plc $285.98 USD -9.43
Bayer AG €137.91 EUR +2.72
Bristol-Myers Squibb Co $65.19 USD -0.60
Medtronic PLC $76.51 USD -1.10
View Industry Companies
 

Industry Analysis

GS7

Industry Average

Valuation GS7 Industry Range
Price/Earnings 26.4x
Price/Sales 3.1x
Price/Book 16.9x
Price/Cash Flow 26.4x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.